Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3305677 · 5 trials · 4 indications
Each ISA will detail the intervention specific analysis.
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3305677 Obesity ISA OXA1 | EXPERIMENTAL | Participants will receive LY3305677 or placebo subcutaneously (SC). Each ISA will detail the intervention specific analysis. |
| LY3841136 Obesity ISA LAA1 | EXPERIMENTAL | Participants will receive LY3841136 or placebo SC. Each ISA will detail the intervention specific analysis. |
| LY3841136 Obesity ISA LAA2 | EXPERIMENTAL | Participants will receive LY3841136, tirzepatide and placebo SC. Each ISA will detail the intervention specific analysis. |
| LY3549492 Obesity ISA GN01 | EXPERIMENTAL | Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis. |
| LY3549492 Obesity ISA GN02 | EXPERIMENTAL | Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis. |
| Obesity ISA MC01 | EXPERIMENTAL | Participants will receive macupatide, eloralintide, and placebo SC. Each ISA will detail the intervention specific analysis. |
| LY3305677 | EXPERIMENTAL | LY3305677 administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3305677 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| LY3841136 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| Tirzepatide | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| LY3549492 | DRUG | Administered orally. ISA specific interventions will be listed in the ISA. |
| LY3532226 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| Placebo | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
Inclusion Criteria: * Have a body mass index (BMI) * ≥30 kilogram/square meter (kg/m²), or * ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity * Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss. Exclusion Criteria:...
Top 20 of 32 competitors
LY3305677 is an investigational small molecule being developed by Eli Lilly and Company for metabolic conditions, including obesity, overweight, and type 2 diabetes. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY3305677 is a small molecule, but its specific molecular target has not been disclosed in available clinical trial information. It is being studied for its effects on metabolic conditions such as obesity and type 2 diabetes.
LY3305677 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
LY3305677 is in Phase 1 clinical development. It has completed multiple Phase 1 trials in healthy participants and in patients with type 2 diabetes, and is currently being evaluated in a Phase 2 master protocol study for obesity or overweight.
LY3305677 has been studied in several clinical trials, including NCT03325387 in healthy participants, NCT03928379 in type 2 diabetes, and NCT05623839 in obesity or overweight. It is currently being evaluated in the Phase 2 master protocol study NCT06143956.
LY3305677 is not the same as LY900038. LY900038 is the master protocol study number for a Phase 2 trial that evaluates multiple investigational drugs, including LY3305677, in participants with obesity or overweight.